197229-63-3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 33630-99-8 3-amino-2-pyridone 
• 33630-99-8 2-hydroxy-3-aminopyridine 
• 6332-56-5 2-hydroxy-3-nitropyridine 
• 6332-56-5 3-nitropyridone 

Downstream Products

• 343566-41-6 trans-(2'S,4S)-4-(2'-{3''-[(5'''-methylisoxazole-3'''carbonyl)amino]-2''-oxo-2''H-pyridin-1''-yl}-3'-phenylpropionylamino)-6-(tritylcarbamoyl)hex-2-enoic acid ethyl ester 
• 343566-40-5 trans-(2'S,4S)-4-[2'-(3''-tert-butoxycarbonylamino-2''-oxo-2''H-pyridin-1''-yl)-3'-phenylpropionylamino]-6-(tritylcarbamoyl)hex-2-enoic acid ethyl ester 
• 1027996-35-5 (E)-(S)-4-{(S)-2-[3-(2,2-Dimethyl-propionylamino)-2-oxo-2H-pyridin-1-yl]-3-phenyl-propionylamino}-6-(trityl-carbamoyl)-hex-2-enoic acid ethyl ester 
• 1026715-58-1 (E)-(S)-4-[(S)-2-(3-Acetylamino-2-oxo-2H-pyridin-1-yl)-3-phenyl-propionylamino]-6-(trityl-carbamoyl)-hex-2-enoic acid ethyl ester 
• 422322-95-0 (1''S,2'S)-(1-{1'-[1''-hydroxymethyl-3''-(tritylcarbamoyl)propylcarbamoyl]-2'-phenylethyl}-2-oxo-1,2-dihydropyridin-3-yl)carbamic acid tert-butyl ester 
• 343566-39-2 (1''S,2'S)-(1-{1'-[1''-(tert-butyldimethylsilanyloxymethyl)-3''-(tritylcarbamoyl)propylcarbamoyl]-2'-phenylethyl}-2-oxo-1,2-dihydropyridin-3-yl)carbamic acid tert-butyl ester 
• 99780-98-0 (+/-)-3-<(tert-butoxycarbonyl)amino>-2-piperidone 

Relevant academic research and scientific papers

Optimization of peptide-based inhibitors targeting the HtrA serine protease in Chlamydia: Design, synthesis and biological evaluation of pyridone-based and N-Capping group-modified analogues

The obligate intracellular bacterium Chlamydia trachomatis (C. trachomatis) is responsible for the most common bacterial sexually transmitted infection and is the leading cause of preventable blindness, representing a major global health burden. While C.

A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS

A class of mono-protected 3-amino-2- hydroxypyridine (MPAHP) ligands that enable the meta- C-H arylation of anilines, phenols, phenylacetic acids, and biologically relevant heterocyclic compounds using norbornene as a transient mediator is disclosed. The applicability of this meta-arylation methodology in the pharmaceutical industry is illustrated for heteroaryl substrates and heteroaryl iodide coupling partners, a feat made possible by using the MPAHP ligand. The enabling nature of MPAHP ligands to achieve other meta-C-H functionalization processes is also illustrated by the development of a meta-C-H amination reaction and a meta-C-H alkynylation reaction.

Substitituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade

The invention relates to substituted polycyclic aryl and heteroaryl pyridone compounds useful inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics

The structure-based design, chemical synthesis, and biological evaluation of various 2-pyridone-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of a peptidomimetic binding determinant and a Michael acceptor moiety, which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. The 2-pyridone-containing inhibitors typically display improved 3CP inhibition properties relative to related peptide-derived molecules along with more favorable antiviral properties. The cocrystal structure of one pyridone-derived 3CP inhibitor complexed with HRV-2 3CP is also described along with certain ab initio conformation analyses. Optimization of the 2-pyridone-containing compounds is shown to provide several highly active 3CP inhibitors (kobs/[I] > 500 000 M-1 s-1) that function as potent antirhinoviral agents (EC50 = 0.05 μM) against multiple virus serotypes in cell culture. One 2-pyridone-containing 3CP inhibitor is shown to be bioavailable in the dog after oral dosing (F = 48%).

Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis

Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the picornaviral 3C protease. Also disclosed are compounds of the formula: where the formula variables are as defined herein that advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as rhinovirus 3C proteases. Intermediates and synthetic methods for preparing such compounds are also described.

Studies towards 4-C-alkylation of pyridin-2(1H)-one derivatives.

In order to obtain 4-C-alkylated pyridin-2(1H)-ones, two strategies were studied: nucleophilic substitution of 4-chloro-3-nitropyridinone derivatives which essentially failed and lithiations of 2-methoxy-3-pivaloylaminopyridines which gave the expected products.